đŸ“£ VC round data is live. Check it out!

Alpha Tau Medical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Alpha Tau Medical and similar public comparables like SS Innovations, MedCap, InMode, PHC Holdings and more.

Alpha Tau Medical Overview

About Alpha Tau Medical

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation’s limited range. The company derives maximum revenue from Israel.


Founded

2015

HQ

Israel

Employees

125

Financials (LTM)

Revenue: $518K
EBITDA: ($46M)

EV

$745M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Alpha Tau Medical Financials

Alpha Tau Medical reported last 12-month revenue of $518K and negative EBITDA of ($46M).

In the same LTM period, Alpha Tau Medical generated $117K in gross profit, ($46M) in EBITDA losses, and had net loss of ($48M).

Revenue (LTM)


Alpha Tau Medical P&L

In the most recent fiscal year, Alpha Tau Medical reported revenue of - and EBITDA of ($41M).

Alpha Tau Medical is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Alpha Tau Medical
LTMLast FY202320242025202620272028
Revenue$518K----
Gross Profit$117K----
Gross Margin23%----
EBITDA($46M)($41M)($28M)($30M)($41M)
EBITDA Margin(8926%)----
EBIT Margin(8872%)----
Net Profit($48M)($43M)($29M)($32M)($43M)
Net Margin(9284%)----

Financial data powered by Morningstar, Inc.

Alpha Tau Medical Stock Performance

Alpha Tau Medical has current market cap of $807M, and enterprise value of $745M.

Market Cap Evolution


Alpha Tau Medical's stock price is $8.93.

Alpha Tau Medical share price decreased by 17.5% in the last 30 days, and increased by 187.0% in the last year.

Alpha Tau Medical has an EPS (earnings per share) of $-0.47.

See more trading valuation data for Alpha Tau Medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$745M$807M-7.6%-17.5%26.3%187.0%$-0.47

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Alpha Tau Medical Valuation Multiples

Alpha Tau Medical trades at 1437.3x EV/Revenue multiple, and (16.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Alpha Tau Medical

EV / Revenue (LTM)


Alpha Tau Medical Financial Valuation Multiples

As of June 3, 2026, Alpha Tau Medical has market cap of $807M and EV of $745M.

Alpha Tau Medical has a P/E ratio of (16.8x).

LTMLast FY202320242025202620272028
EV/Revenuen/m----
EV/EBITDA(16.1x)(18.2x)(26.6x)(24.5x)(18.2x)
EV/EBIT(16.2x)(17.6x)(20.9x)(20.7x)(17.6x)
EV/Gross Profitn/m----
P/E(16.8x)(18.9x)(27.7x)(25.4x)(18.9x)
EV/FCF-(22.7x)(30.6x)(33.8x)(22.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Alpha Tau Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Alpha Tau Medical Margins & Growth Rates

Alpha Tau Medical grew EBITDA by 30% in the last fiscal year.

See estimated margins and future growth rates for Alpha Tau Medical

Alpha Tau Medical Margins

2026202720282029
Gross Margin23%
EBITDA Margin(4344%)
EBIT Margin(4153%)
Net Margin(4527%)

Alpha Tau Medical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
EBITDA Growth30%8%35%30%
EBIT Growth21%1%17%21%
Net Profit Growth30%9%34%30%
FCF Growth-(10%)49%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Alpha Tau Medical Operational KPIs

Alpha Tau Medical's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for Alpha Tau Medical
LTMLast FY202620272028
Rule of 40(7880%)-
Bessemer Rule of X(6311%)-
Revenue per Employee-$0.0M
Opex per Employee-$0.3M
S&M Expenses to Revenue310%-
G&A Expenses to Revenue1695%-
R&D Expenses to Revenue6833%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Alpha Tau Medical Competitors

Alpha Tau Medical competitors include SS Innovations, MedCap, InMode, PHC Holdings, Oculis Holding, Barco, Anteris Technologies US, QuidelOrtho, LifeTech Scientific and Dynavox Group.

Most Alpha Tau Medical public comparables operate across Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
SS Innovations18.8x-(133.9x)-
MedCap3.6x3.5x16.3x15.7x
InMode0.9x0.9x3.3x3.7x
PHC Holdings0.9x0.9x6.4x6.3x
Oculis Holding301.8x353.8x(4.3x)(4.4x)
Barco0.6x0.6x4.3x4.4x
Anteris Technologies US327.4x141.9x(7.0x)(6.3x)
QuidelOrtho1.3x1.3x6.1x6.0x

This data is available for Pro users. Sign up to see all Alpha Tau Medical competitors and their valuation data.

Start Free Trial

Alpha Tau Medical VC Funding History

Before going public, Alpha Tau Medical raised $60M in total equity funding, across 2 rounds.


Alpha Tau Medical Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-20Series BMedison Ventures; OurCrowd; Shavit Capital$26M-Alpha Tau Medical is a clinical-stage oncology company developing Alpha DaRT, an innovative alpha-radiation cancer therapy using Diffusing Alpha-emitters Radiation Therapy seeds for short-range tumor destruction. The company, now publicly traded as DRTS on Nasdaq, has focused on clinical trials and regulatory approvals, including Japanese marketing approval for head and neck cancer and U.S. FDA IDE for prostate cancer studies. Manufacturing capacity in New Hampshire supports up to 400,000 sources annually. Net losses have grown, reaching $42.6 million in 2025 from $31.8 million in 2024, driven by rising R&D expenses ($32.1 million in 2025) and G&A ($8.4 million). Earlier periods show losses like $9 million for December 2020 and escalating to $41 million by March 2022. Cash reserves stood at $76.9 million as of December 31, 2025, funding clinical advancement.
Sep-18Series AAlan Patricof; Medison Ventures; OurCrowd; Regah Ventures; Shavit Capital$34M-Alpha Tau Medical is an Israeli medical device company developing Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a breakthrough alpha-radiation-based cancer treatment designed to deliver high-precision radiation directly to solid tumors while minimizing damage to surrounding healthy tissue. In September 2018, Alpha Tau announced a $29 million Series B funding round led by Shavit Capital, with participation from OurCrowd, Medison Ventures (the venture capital arm of Medison Pharma), and prominent international investors Sir Ronald Cohen and Alan Patricof, co-founders of Apax Partners. The funding was earmarked to accelerate the company's global clinical research program, establish new production facilities for radioactive DaRT seeds, and expand clinical trials across multiple cancer types including breast, oral cavity, pancreatic, and skin cancers. By 2019, Alpha Tau had reported Phase I clinical trial results showing that 78% of patients with brain, neck, and squamous cell carcinoma skin cancers achieved complete tumor disappearance, with 61% of these patients having previously failed other treatments. The company was conducting concurrent trials for five additional cancer indications. In March 2022, Alpha Tau completed a SPAC merger with Healthcare Capital Corp. (Nasdaq: HCCC) at a $1 billion post-money valuation, marking a significant validation of its technology platform and clinical progress since the 2018 funding round.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Alpha Tau Medical

When was Alpha Tau Medical founded?Alpha Tau Medical was founded in 2015.
Where is Alpha Tau Medical headquartered?Alpha Tau Medical is headquartered in Israel.
How many employees does Alpha Tau Medical have?As of today, Alpha Tau Medical has over 125 employees.
Who is the CEO of Alpha Tau Medical?Alpha Tau Medical's CEO is Uzi Sofer.
Is Alpha Tau Medical publicly listed?Yes, Alpha Tau Medical is a public company listed on Nasdaq.
What is the stock symbol of Alpha Tau Medical?Alpha Tau Medical trades under DRTS ticker.
When did Alpha Tau Medical go public?Alpha Tau Medical went public in 2022.
Who are competitors of Alpha Tau Medical?Alpha Tau Medical main competitors include SS Innovations, MedCap, InMode, PHC Holdings, Oculis Holding, Barco, Anteris Technologies US, QuidelOrtho, LifeTech Scientific, Dynavox Group.
What is the current market cap of Alpha Tau Medical?Alpha Tau Medical's current market cap is $807M.
What is the current revenue of Alpha Tau Medical?Alpha Tau Medical's last 12 months revenue is $518K.
What is the current revenue growth of Alpha Tau Medical?Alpha Tau Medical revenue growth (NTM/LTM) is 1046%.
What is the current EV/Revenue multiple of Alpha Tau Medical?Current revenue multiple of Alpha Tau Medical is 1437.3x.
Is Alpha Tau Medical profitable?No, Alpha Tau Medical is not profitable.
What is the current EBITDA of Alpha Tau Medical?Alpha Tau Medical has negative EBITDA and is not profitable.
What is Alpha Tau Medical's EBITDA margin?Alpha Tau Medical's last 12 months EBITDA margin is (8926%).
What is the current EV/EBITDA multiple of Alpha Tau Medical?Current EBITDA multiple of Alpha Tau Medical is (16.1x).
How many companies Alpha Tau Medical has acquired to date?Alpha Tau Medical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Alpha Tau Medical has invested to date?Alpha Tau Medical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Alpha Tau Medical

Lists including Alpha Tau Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial